Peptide Epitalon activates chromatin at the old age

OBJECTIVES and design. We have studied the effect of synthetic peptide Epitalon on the activity of ribosomal genes, denaturation parameters of total heterochromatin, polymorphism of structural C-heterochromatin and the variability of facultative heterochromatin in cultured lymphocytes of persons aged 76-80 years. RESULTS: The obtained data demonstrate that Epitalon induces the activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin and the release of genes repressed due to the age-related condensation of euchromatic chromosome regions. CONCLUSIONS: Epitalon has shown its ability to activate chromatin by modifying heterochromatin and heterochromatinized chromosome regions in the cells of older persons.     

Role of FMRFamide in the reproduction of Octopus vulgaris: molecular analysis and effect on visual input

As a part of continuous research on the neurobiology of the cephalopods in general, and the neuroendocrine control of reproduction in Octopus vulgaris in particular, the presence, the molecular analysis and the effect of FMRFamide on the screening-pigment migration in the visual system have been analysed. FMRFamide immunoreactive fibres are present in the outer plexiform layer of the retina as well as in the plexiform zone of the deep retina. These fibres presumably come from optic and olfactory lobes. We isolated an incomplete Octopus FMRFamide cDNA which encodes an amino terminal truncated precursor containing several FMRFamide-related peptides (FaRPs) showing a high degree of identity with the FaRPs encoded in the precursor of Sepia officinalis, except for the presence of an Rpamide related peptide, present only in cnidarians. Finally, stimulation of isolated retina demonstrated that the effect of this tetrapeptide, coupled with dopamine, is the induction of an extreme adaptation of the retina to the light condition. This situation de facto inhibits sexual maturation. Our results on the effect of FMRFamide on the retina confirm the suggested hypothesis that this peptide plays an inhibitory role on the activity of optic gland.     

Effects of Livagen and Epitalon, New Peptide Bioregulators, on Enkephalin-Degrading Enzymes from Human Serum

The effects of new peptide bioregulators—Livagen (Lys-Glu-Asp-Ala) and Epitalon (Ala-Glu-Asp-Gly)—on the endogenous opioid system was studied. In particular, attention was focused on their ability to change the activity of enkephalin-degrading enzymes of blood serum and interact with opioid receptors of the brain membrane fraction. Enkephalinase activity was assayed in vitro by the rate of ³H-Leu-enkephalin hydrolysis in the presence of Livagen and Epitalon. These peptides inhibited enkephalin-degrading enzymes of human serum. Livagen proved to be more efficient than some well-known peptidase inhibitors, such as puromycin, leupeptin, and D-PAM. The dose–inhibitory effect curves for Livagen and Epitalon were plotted; their IC₅₀ equaled 20 and 500 M, respectively. The interaction between the peptides and opioid receptors was estimated using a radioreceptor method with [³H][D-Ala², D-Leu⁵]-enkephalin. No interaction was observed between the peptides and - or -opioid receptors of the membrane fraction from the rat brain.     

Morphine-like activity of the enkephalin analog Tyr-D-Ala-Gly-Phe-NH2

The analgetic activity of the tetrapeptide enkephalin analog, its influence on the interneuronal transmission of excitation in various areas of the central nervous system and on opiate receptors of vas deferens were studied. The tetrapeptide was found to have a marked analgetic effect during intravenous injection to mice but to be less active than morphine. The tetrapeptide as well as morphine inhibited the impulse summation in rabbits and both spontaneous and bradykinin-induced neuronal activity in the rat sensory motor cortex. The tetrapeptide inhibited the contractions of isolated vas deferens in mice. The opiate antagonist naloxone eliminated both analgetic effect of the tetrapeptide and its inhibitory effect on the impulse summation, neuronal activity and contractions of vas deferens.     

Interaction of an analog of the E1 site of tetrapeptide Gly-Pro-Arg-Pro with the D1 site of two forms of monomeric fibrin

Two monomeric fibrin forms differing in a set of polymerization sites (fibrin desAA and fibrin-desAABB) are inhibited to a different extent by tetrapeptide Gly-Pro-Arg-Pro which simulates a moiety of polymerization site E1. The lesser sensitivity of fibrin-desAABB polymerization to the inhibiting tetrapeptide is due to the presence of active site E2 in it. A shape of the concentration dependence curve of the inhibitory effect of tetrapeptide Gly-Pro-Arg-Pro on the polymerization of both fibrin types is similar to the previously found curve for fibrinogen and its fragments--specific inhibitors of polymerization. Ca2+ intensifies inhibition of fibrin-desAABB polymerization by tetrapeptide Gly-Pro-Arg-Pro twice as much as that of fibrin-desAA evidently due to the peptide blockage of sites D2. An increase of the ionic strength from 0.15 to 0.3 enhances the inhibitory effect of the tetrapeptide on polymerization of two monomeric fibrin forms.     

Effect of a novel tetrapeptide derivative in a rat model of isoproterenol induced myocardial necrosis

Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats. Cardiotoxicity of three different doses of ISO were studied using physiological, biochemical and histopathological parameters. The effects of single and double dose of ISO were analysed, which illustrated that single ISO dose was more cardiotoxic than double ISO dose due to ischemic preconditioning. The tetrapeptide derivatives L-lysine-L-arginine-L-aspartic acid-L-serine (tetrapeptide A) and di-tert.butyloxycarbonyl-L-lysine-L-arginine-L-aspartic acid-tert.butyl O-tert.butyl-L-serinate (tetrapeptide B) along with acetylsalicylic acid as positive control were analysed at different time points for their cardioprotective effect. The results demonstrated that optimal protective effects were observed by pretreatment with 5 mg/kg of tetrapeptide B and this was found to be slightly better than that of acetylsalicylic acid. A lesser degree of cardioprotection was noticed when low doses of tetrapeptide B were administered. This study clearly showed that single dose of ISO (50 mg/kg, s.c.) induced myocardial necrosis could be used as a model to assess cardiovascular drugs and in this model, it was demonstrated that the tetrapeptide B could exhibit optimal cardioprotective effect.     

A novel surface-active peptide derivative exhibits in vitro inhibition of platelet aggregation

A tetrapeptide corresponding to a region of the N-terminal portion of lactotransferrin with hydrophobic alkyl groups at the terminal ends was synthesized and its physicochemical properties as well as its effect on thrombin-stimulated platelet aggregation were examined. The tetrapeptide derivative, in the aggregated state, produced inhibitory effect on platelet aggregation. The concentration dependent activity of the peptide was analyzed in the light of micelle formation, with the micellar aggregate comprising four tetrapeptide units. The unique action of this peptide derivative on the inhibition of platelet aggregation might be useful in the development of potent antithrombotic drugs.     

C-terminal domain of apolipoprotein CII as both activator and competitive inhibitor of lipoprotein lipase.

In this study we have prepared peptides of the C-terminal domain of apolipoprotein CII (ApoCII) by a solid-peptide-synthesis technique and demonstrated that the C-terminal tetrapeptide, Lys-Gly-Glu-Glu, represents an inhibitor of lipoprotein lipase. The tetrapeptide not only inhibits the basal activity of lipoprotein lipase, but also blocks the activation effect of native ApoCII. The lengthening of this tetrapeptide resulted in a corresponding increase in affinity for lipoprotein lipase. This suggested that amino acids other than those of the C-terminal tetrapeptide also contribute to the binding affinity of ApoCII for lipoprotein lipase. On the basis of an essential requirement of the ApoCII terminal domain for binding to lipoprotein lipase, we suggest that the initial interaction of ApoCII, mediated via the C-terminal tetrapeptide, promotes the proper alignment of ApoCII with lipoprotein lipase, followed by the weak interaction of the ApoCII activator domain with the lipoprotein lipase activator site, enhancing the lipolysis process.     

Analgesic and Antipyretic Activities of a Novel Tetrapeptide in Rats

The efficacy of a novel tetrapeptide sequence, FLPS (Phe-Leu-Pro-Ser), to alleviate severe pain associated with surgical incision is demonstrated in the Brennan model, a model used for developing new drugs for postoperative pain in humans. The tetrapeptide (100 mg/kg dose) administered by subdermal injection completely alleviated post-incisional pain in rats using the hindpaw withdrawal as an endpoint response. When the tetrapeptide (0.15 mg/paw) was topically applied to the vicinity of the surgical wound, it also alleviated pain. Statistically significant increases in pain threshold (assessed by von Frey filaments pressed against the surgical wound, 15–20 min after dosing) were observed on the day of surgery and on the third day post-surgery. Up to a 0.5°C decrease in body temperature under basal conditions and yeast-provoked pyrexia was observed at doses that alleviate pain. The tetrapeptide does not exhibit any significant anti-edema activity in carrageenan-induced hindpaw edema, and does not affect human recombinant cyclooxygenase-2 activity, indicating that the analgesic property of the tetrapeptide is unlikely to be mediated through inflammatory pathways. The tetrapeptide at 10 μM, a dose that is sufficient to increase the pain threshold in rats, does not compete with naloxone for the opioid receptors in membrane preparations from rat brain, indicating that it does not mediate its effect through the opioid receptors. It also does not bind to the vanilloid receptor, indicating that peripheral vanilloid receptors are not involved in pain relief by the tetrapeptide.     

The immunostimulating properties of cholecystokinin octapeptide and its fragments]

Immunostimulating properties of cholecystokinin octapeptide (CCK-8) were evaluated in experiments on adult normal and thymectomized mice, in vitro. It was shown that CCK-8 stimulates IgM-PFC production to SRBC, but does not change the immune response to Vi-antigen. CCK-8 increases the number of Thy-I+ spleen T cells and restores thymus-dependent immune response in thymectomized mice. CCK-8 has no effect on neutrophil phagocytosis activity in vitro. The immunostimulating activity of CCK-8 is related mainly to C-terminal fragment (identical to pentagastrin tetrapeptide) since the N-terminal CCK-8 tetrapeptide displays negligible effect in all tests.     

Further Characterization of a Novel Tetrapeptide with an Analgesic Action in the Central and Peripheral Nervous System in Rats

The novel tetrapeptide FLPS has been previously shown to induce antinociception in a model of post-incisional pain in the rat. It has been demonstrated in membrane preparations of rat brain that 10 μM tetrapeptide did not compete with [³H]naloxone for its binding site on the opioid receptors which differentiates it from typical opioids. In the first set of experiments, the stimulation of [³⁵S]GTPγS binding by the tetrapeptide to membrane preparations of recombinant cell lines expressing human μ, δ, and κ receptors has been investigated. The specific [³⁵S]GTPγS binding did not change in the presence of 100 μM tetrapeptide and DAMGO, DPDPE, or U-69593 at submaximal and maximal concentrations, indicating that the tetrapeptide was not an agonist or antagonist of the opioid receptors and it did not stimulate or blocked the stimulation of G-proteins coupled to these receptors. Studies with naloxone and naloxone methiodide pretreatment suggested that the tetrapeptide was either directly or indirectly affected by a naloxone-binding site located primarily within the central nervous system and to a lesser extent in the periphery. Naloxone pretreatment had a dual effect on morphine antinociception based on the concentration used. At 2 mg/kg, naloxone competed reversibly with 25 mg/kg morphine on its binding site on the opioid receptors, while at 5.4 mg/kg it blocked antinociception induced by 10 mg/kg morphine, 2.7 mg/kg aspirin, or 75 mg/kg tetrapeptide. These data suggest that a new naloxone-binding site is involved in alleviation of pain by at least three classes of analsegics (opioids, cycloogenase 2 inhibitors, and the tetrapeptide). The biological activity of the peptide was discovered first and the mechanism of action is now being studied. In an attempt to identify the therapeutic target of the tetrapeptide, a total of 23 radioligand binding assays to targets within the CNS were conducted. The results of these assays were negative and they reinforce the notion that the tetrapeptide activates an unknown mechanism involved in pain perception after surgery.     

The comparative analysis of the effect of oligopeptides and amino acids on the development of rat different tissue culture

The effect the synthetic tetra-, tripeptides and amino acids, composed them, in concentration 10(-12) M was investigated in organotypic tissue culture on the cell proliferation and apoptosis development in six tissue explants (ecto-, meso- and entodermal genesis) in rats at age 3 months old. The tetrapeptide demonstrated the greater tissue-specificity, as compared to the tripeptides and amino acids. Each tetrapeptide stimulated proliferation in only one corresponded tissue type. Less tissue-specificity was observed in the tripeptides, which stimulated proliferation and apoptosis in one (one case)--four tissues. The amino acids stimulated proliferation and apoptosis in three--five tissues. It can be suggested, that tissue-specificity in these biologically active substances is depended on the structure complexity. It is discussed, that the tetrapeptide tissue-specificity is related to the complementar interaction to the DNA site-specific blocks.     

The role of complementary E2 and D2 centers in the reaction between fibrin and fibrinogen

The effect of fibrinogen on the two steps of polymerization of two fibrin forms differing in the set of polymerization sites (fibrin-desAA and fibrin-desAABB) was studied. It was shown that fibrinogen inhibited the protofibril growth and fibril formation at the stage of lateral aggregation more effectively with fibrin-desAABB than with fibrin desAA. When the fibrinogen D2-site was blocked by tetrapeptide Gly-His-Arg-Pro, the key structure of the E2-site, the inhibitory activity of fibrinogen diminished. A conclusion is drawn that the high susceptibility of fibrin-desAABB to fibrinogen is due to the interaction of the E2-active site with the D2-site of the fibrinogen molecule. The concentration dependence of the tetrapeptide Gly-His-Arg-Pro-induced inactivation of fibrinogen and the effects of temperature and Ca2+ on the tetrapeptide interaction with fibrinogen were investigated.     

The effect of chronic activation and block of the dopamin- and enkephalinergic systems of the neostriatum on conditioned-reflex behavior abd dopamine metabolism in the nigrostriatal system of rats]

Were studied the effects of bilateral daily intrastriatal microinjections in the course of two weeks of amphetamine (45 mcg), haloperidol (5 mcg), naloxone (5 mcg), and enkephalin synthetic tetrapeptide analogue (15 mcg) on behaviour and the level of dopamine and its metabolites in the striatum and substantia nigra of rats. Amphetamine improved but haloperidol impaired conditioned avoidance response realization in a shuttle-box and produced parkinsonian-like akinetic status. Naloxone was behaviourally uneffective but the tetrapeptide produced the obvious cataleptic status with plastic rigidity of the skeletal muscles. Both amphetamine and haloperidol lowered significantly striatal dopamine level and increased the level of its metabolites. The tetrapeptide produced the opposite neurochemical effect. Possible origin of discoordination between behavioural and neurotransmitter changes are discussed.     

Pressure-induced thermostabilization of glutamate dehydrogenase from the hyperthermophile Pyrococcus furiosus.

In this paper, elevated pressures up to 750 atm (1 atm = 101 kPa) were found to have a strong stabilizing effect on two extremely thermophilic glutamate dehydrogenases (GDHs): the native enzyme from the hyperthermophile Pyrococcus furiosus (Pf), and a recombinant GDH mutant containing an extra tetrapeptide at the C-terminus (rGDHt). The presence of the tetrapeptide greatly destabilized the recombinant mutant at ambient pressure; however, the destabilizing effect was largely reversed by the application of pressure. Electron spin resonance (ESR) spectroscopy of a spin-label attached to the terminal cysteine of rGDHt revealed a high degree of mobility, suggesting that destabilization is due to weakened intersubunit ion-pair interactions induced by thermal fluctuations of the tetrapeptide. For both enzymes, the stabilizing effect of pressure increased with temperature as well as pressure, reaching 36-fold for rGDHt at 105 degrees C and 750 atm, the largest pressure-induced thermostabilization of an enzyme reported to date. Stabilization of both native GDH and rGDHt was also achieved by adding glycerol. Based on the kinetics of thermal inactivation and the known effects of glycerol on protein structure, a mechanism of pressure-induced thermostabilization is proposed.     

Cholecystokinin octapeptide (CCK 26–33), nonsulfated octapeptide and tetrapeptide (CCK 30–33) in rat brain: Analysis by high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA)

Cholecystokinin carboxyterminal octa- and tetrapeptide concentrations have been measured in rat brain by a combination of high pressure liquid chromatography and radioimmunoassay. The sulfated octapeptide is the predominant form of Cholecystokinin in rat brain (approx. 80%). The concentration of the tetrapeptide represents 5–10% of that of the sulfated octapeptide in molar terms, depending upon the brain region. In addition to the tetrapeptide, a peptide with the properties of Cholecystokinin octapeptide in its nonsulfated form could be detected in concentrations similar to those of the tetrapeptide.     

High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery

The airway-to-blood absorption of the mu-selective opioid tetrapeptide agonist Tyr-D-Arg-Phe-Phe-NH(2) (MW 631) was investigated in the isolated, perfused, and ventilated rat lung model. The lung metabolism of the peptide was compared after airway and vascular delivery. The concentrations of the parent tetrapeptide and five of its metabolites in the perfusate and in bronchoalveolar lavage fluid were analyzed by LC-MS.The metabolism of the peptide was higher after delivery to the airways compared to vascular delivery. However, the tetrapeptide was highly transported from the air-to-blood side to an extent of 47.8 +/- 10.7% in 2 h. In conclusion, the results prompt investigations of the pulmonary route as a successful alternative to parenteral delivery for this tetrapeptide.     

Support vector machines for the classification and prediction of beta-turn types.

The support vector machines (SVMs) method is proposed because it can reflect the sequence-coupling effect for a tetrapeptide in not only a beta-turn or non-beta-turn, but also in different types of beta-turn. The results of the model for 6022 tetrapeptides indicate that the rates of self-consistency for beta-turn types I, I', II, II', VI and VIII and non-beta-turns are 99.92%, 96.8%, 98.02%, 97.75%, 100%, 97.19% and 100%, respectively. Using these training data, the rate of correct prediction by the SVMs for a given protein: rubredoxin (54 residues. 51 tetrapeptides) which includes 12 beta-turn type I tetrapeptides, 1 beta-turn type II tetrapeptide and 38 non-beta-turns reached 82.4%. The high quality of prediction of the SVMs implies that the formation of different beta-turn types or non-beta-turns is considerably correlated with the sequence of a tetrapeptide. The SVMs can save CPU time and avoid the overfitting problem compared with the neural network method.     

Isolation from porcine antral mucosa of a hexapeptide corresponding to the C-terminal sequence of gastrin

The present studies were undertaken to confirm reports of high concentrations of the C-terminal tetrapeptide of gastrin in hog antral mucosa. A method was developed whereby synthetic tetrapeptide added to boiling water extracts of hog antral mucosa could be purified to homogeneity by adsorption to Amberlite XAD2 resin, ion exchange chromatography on DEAE cellulose, and reverse phase HPLC. The product had the amino acid composition of gastrin tetrapeptide. When the same method was used on antral mucosa without prior addition of synthetic G4, several small peaks of material with C-terminal immunoreactivity could be found in DEAE column eluates but none could be unequivocally identified as the tetrapeptide. In the same column runs there was a relatively large peak of immunoreactivity eluting later than the tetrapeptide. This material was purified to homogeneity by HPLC and on the basis of its amino acid composition and sequence was identified as the C-terminal hexapeptide of gastrin.